Center for Cytokine Storm Treatment & Laboratory
Our Vision
The CSTL’s vision is a world where all patients with Castleman disease, COVID-19, and other cytokine storm disorders live full lives in quality and quantity thanks to effective treatments and biomarkers.
Our Mission
The CSTL’s mission is to conduct groundbreaking translational research on Castleman disease, COVID-19, and other cytokine storms to discover novel diagnostic biomarkers and therapeutics, identify optimal treatment approaches, and provide world-class patient care.
The CSTL pursues its mission through basic & translational research, clinical research (ACCELERATE Natural History Registry; CORONA: COvid19 Registry of Off-Label & New Agents), clinical trials (NCT03933904), and multi-disciplinary patient care.
The CSTL is a Program of Excellence of the Penn Orphan Disease Center.
Latest News
New Article Published in Journal of Clinical Investigations Insight
A paper recently published in the Journal of Clinical Investigation Insight seeks to determine what's happening at the cellular level in the immune sy...
New Article Published in Infectious Diseases & Therapy
A new paper published in Infectious Diseases & Therapy catalogued every drug used to treat COVID-19 in the medical literature.
New Article Published in Blood
A study recently published in Blood is one of the largest research studies of Castleman Disease ever performed. Researchers used 26 samples from iMCD ...